Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates
Provided By GlobeNewswire
Last update: Aug 6, 2025
– On track for proof-of-concept Phase 1b data no later than this fall in participants with recurrent genital herpes for long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidates, ABI-5366 and ABI-1179 –
Read more at globenewswire.com
